211 related articles for article (PubMed ID: 16846533)
1. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
Souglakos J; Vamvakas L; Apostolaki S; Perraki M; Saridaki Z; Kazakou I; Pallis A; Kouroussis C; Androulakis N; Kalbakis K; Millaki G; Mavroudis D; Georgoulias V
Breast Cancer Res; 2006; 8(4):R36. PubMed ID: 16846533
[TBL] [Abstract][Full Text] [Related]
2. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Ignatiadis M; Kallergi G; Ntoulia M; Perraki M; Apostolaki S; Kafousi M; Chlouverakis G; Stathopoulos E; Lianidou E; Georgoulias V; Mavroudis D
Clin Cancer Res; 2008 May; 14(9):2593-600. PubMed ID: 18451221
[TBL] [Abstract][Full Text] [Related]
5. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
6. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
[TBL] [Abstract][Full Text] [Related]
7. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
Ignatiadis M; Perraki M; Apostolaki S; Politaki E; Xenidis N; Kafousi M; Stathopoulos E; Lianidou E; Sotiriou C; Georgoulias V; Mavroudis D
Clin Breast Cancer; 2007 Dec; 7(11):883-9. PubMed ID: 18269779
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
[TBL] [Abstract][Full Text] [Related]
9. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
10. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
Pestrin M; Bessi S; Galardi F; Truglia M; Biggeri A; Biagioni C; Cappadona S; Biganzoli L; Giannini A; Di Leo A
Breast Cancer Res Treat; 2009 Dec; 118(3):523-30. PubMed ID: 19597704
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
[TBL] [Abstract][Full Text] [Related]
12. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
Buchholz TA; Huang EH; Berry D; Pusztai L; Strom EA; McNeese MD; Perkins GH; Schechter NR; Kuerer HM; Buzdar AU; Valero V; Hunt KK; Hortobagyi GN; Sahin AA
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1337-42. PubMed ID: 15275718
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
15. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
16. Study of HER2/neu status in Qatari women with breast carcinoma.
Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
[TBL] [Abstract][Full Text] [Related]
19. [Detection and clinical significance of circulating tumor cells in peripheral blood of breast cancer patients].
Cai QQ; Huang HQ; Lin TX; Jiang WQ
Ai Zheng; 2005 Jul; 24(7):837-41. PubMed ID: 16004811
[TBL] [Abstract][Full Text] [Related]
20. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection.
Pinzani P; Salvadori B; Simi L; Bianchi S; Distante V; Cataliotti L; Pazzagli M; Orlando C
Hum Pathol; 2006 Jun; 37(6):711-8. PubMed ID: 16733212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]